Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06217185 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

StatusRecruiting
PhasePhase 4
Started2024-01-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2024 (before its estimated December 11, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-02-26
Study Status, Arms and Interventions v1
Re-verified, no change to tracked fields
2024-01-11
Original filing
This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib + Trastuzumab. The aim is to explore the efficacy and safety of Pyrotinib, Trastuzumab, and Taxanes in treating Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Trial Details
NCT Number NCT06217185
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions HER2-positive Breast Cancer, Advanced Breast Cancer
Enrollment 100 participants
Start Date 2024-01-02
Primary Completion 2025-12-11 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-28